SG11202105279SA - Methods of treating myeloproliferative disorders - Google Patents

Methods of treating myeloproliferative disorders

Info

Publication number
SG11202105279SA
SG11202105279SA SG11202105279SA SG11202105279SA SG11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA SG 11202105279S A SG11202105279S A SG 11202105279SA
Authority
SG
Singapore
Prior art keywords
subject
ruxolitinib
day
acetamide
chlorophenyl
Prior art date
Application number
SG11202105279SA
Other languages
English (en)
Inventor
Adrian Senderowicz
Michael Cooper
Original Assignee
Constellation Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Constellation Pharmaceuticals Inc filed Critical Constellation Pharmaceuticals Inc
Publication of SG11202105279SA publication Critical patent/SG11202105279SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SG11202105279SA 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders SG11202105279SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2018/062534 WO2020112086A1 (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
SG11202105279SA true SG11202105279SA (en) 2021-06-29

Family

ID=64734125

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105279SA SG11202105279SA (en) 2018-11-27 2018-11-27 Methods of treating myeloproliferative disorders

Country Status (8)

Country Link
JP (2) JP7453230B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250004357A (cg-RX-API-DMAC7.html)
AU (1) AU2018451360B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010134A2 (cg-RX-API-DMAC7.html)
CA (1) CA3120973A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191489A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105279SA (cg-RX-API-DMAC7.html)
WO (1) WO2020112086A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020112939A1 (en) 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
WO2020112086A1 (en) * 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
AU2021320151A1 (en) * 2020-08-04 2023-02-23 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide for treating thrombocythemia
CN122439254A (zh) 2024-01-18 2026-07-21 株式会社Lg新能源 电极组件、二次电池和电池单元

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) * 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
CN106687463B (zh) 2014-06-20 2019-04-09 星座制药公司 一种乙酰胺类化合物的晶型
WO2020112086A1 (en) * 2018-11-27 2020-06-04 Constellation Pharmaceuticals, Inc. Methods of treating myeloproliferative disorders

Also Published As

Publication number Publication date
WO2020112086A1 (en) 2020-06-04
JP7453230B2 (ja) 2024-03-19
CA3120973A1 (en) 2020-06-04
KR102738936B1 (ko) 2024-12-06
EA202191489A1 (ru) 2021-09-10
AU2018451360B2 (en) 2022-05-26
KR20210095904A (ko) 2021-08-03
KR20250004357A (ko) 2025-01-07
JP2024063214A (ja) 2024-05-10
JP2022519425A (ja) 2022-03-24
BR112021010134A2 (pt) 2021-08-24
AU2018451360A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
ZA202006746B (en) Methods of treatment
IL273693A (en) Treatment of inflammatory disorders
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11202103019WA (en) Methods of treating myeloproliferative disorders
IL267229A (en) Methods of treating ocular disorders
IL267818A (en) Methods for treating neurological disorders
IL269082A (en) Methods of treating lysosomal disorders
IL275654A (en) Methods of treating CASTOR-related disorders
ZA202002066B (en) Compositions and methods for the treatment of eye disorders
IL256424A (en) Methods for treating autoimmune and alloimmune disorders
IL269604A (en) Pentides for the treatment of autoimmune diseases
IL270201B2 (en) A method for treating childhood disorders
IL290983A (en) Treatment methods
GB201607388D0 (en) Treatment of impulsivity-related disorders
LT3458067T (lt) Neurologinių sutrikimų gydymas
SG11202102982QA (en) Methods of treating myeloproliferative disorders
ZA202002910B (en) Treatment of skin disorders
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201918853D0 (en) Methods of treatment
PL3654965T3 (pl) Sposoby leczenia autoimmunologicznych chorób mikronaczyniowych
HK40052689A (en) Methods of treating myeloproliferative disorders
HK40055553A (zh) 治疗骨髓增生性病症的方法
GB201604359D0 (en) Treatment of tissue disorders
IL268504A (en) Methods of treating seizure disorders